drugset / Trial / NCT04338711

A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations

NCT04338711

Phase 1 Completed 23 enrolled Pfizer
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetic (PK) and safety of an age-appropriate tofacitinib Modified Release (MR) formulation with varying level of enteric coating. The effect of food on the PK of age-appropriate tofacitinib MR formulation with the lowest and higher levels of enteric coating will also be assessed.

Timeline

Start
2020-06-17
Primary completion
2020-09-15
Completion
2020-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Tofacitinib Small molecule 10 mg Oral

Indications

No indication recorded.